Akebia Therapeutics is a biopharmaceutical company. Co.'s portfolio includes a late-stage product candidate and a commercial product: Vadadustat, which is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability; and Auryxia® (ferric citrate), which is approved and marketed in the U.S. for two indications which are the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis or the Hyperphosphatemia Indication, and the treatment of iron deficiency anemia (IDA) in adult patients with CKD not on dialysis or the IDA Indication. We show 33 historical shares outstanding datapoints in our AKBA shares outstanding history coverage, used to compute AKBA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AKBA market cap history over the course of time is important for investors
interested in comparing AKBA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AKBA versus a peer is one thing; comparing
AKBA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AKBA can fluctuate over the course of history.
With this page we aim to empower investors researching AKBA by allowing them to research the AKBA market cap history. |
Free AKBA Email Alerts:
Video: The Importance of Market Cap
